Lung cancer annually kills almost 1.6 million people worldwide. Lung cancer recurs because the tumor is resistant to chemotherapy and other drugs that originally drove it into remission. A new strategy involving triple treatment method may keep lung cancer from returning, says a new research.
The study done on mice found that the treatment stopped lung cancer cells from developing resistance to chemotherapy. Cancer often returns after what, at first, seems to be successful treatment. "This finding ran counter to everything we knew about the way tumors develop resistance," said Yosef Yarden at Weizmann Institute of Science, Israel.
The team discovered what happens to cancer cells when they are exposed to the receptor-blocking antibody. One class of relatively common lung cancers, which carry a particular mutation in a receptor on the cell membrane, called EGFR, can be treated with a sort of "wonder drug."
To prevent this from happening, researchers tried to administer another drug, an antibody that is used to treat colon cancer. This drug also obstructs the passing of the growth signal by stopping EGFR. The researchers uncovered the chain of protein communication in the new network that ultimately leads to appearance of the sibling growth receptors.
Yarden and his team created new monoclonal antibodies that could target the two main growth receptor siblings, named HER2 (the target of the breast cancer drug Herceptin) and HER3.
The idea was to give all three antibodies together - the two new ones and the original anti-EGFR antibody - to preempt resistance to the treatment. The team tried the three-pronged approach on mouse models of lung cancer that had the secondary, resistance mutation. In these mice, the tumor growth was almost completely halted.
"Treatment by blocking a single target can cause a feedback loop that ultimately leads to a resurgence of the cancer," Yarden said.
The study appeared in the journal Science Signalling.